Wedbush Increases Earnings Estimates for IDEAYA Biosciences

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) – Investment analysts at Wedbush increased their Q3 2025 earnings per share (EPS) estimates for IDEAYA Biosciences in a note issued to investors on Tuesday, September 2nd. Wedbush analyst R. Driscoll now expects that the company will post earnings per share of $1.37 for the quarter, up from their prior estimate of ($0.94). The consensus estimate for IDEAYA Biosciences’ current full-year earnings is ($3.07) per share. Wedbush also issued estimates for IDEAYA Biosciences’ FY2025 earnings at ($1.29) EPS, Q1 2026 earnings at ($1.03) EPS, Q2 2026 earnings at ($1.07) EPS, Q3 2026 earnings at ($1.10) EPS, Q4 2026 earnings at ($0.56) EPS, FY2026 earnings at ($3.77) EPS, FY2027 earnings at ($3.48) EPS, FY2028 earnings at ($3.13) EPS and FY2029 earnings at ($0.77) EPS.

A number of other equities analysts also recently issued reports on the company. JPMorgan Chase & Co. raised their price objective on IDEAYA Biosciences from $72.00 to $74.00 and gave the stock an “overweight” rating in a research report on Wednesday. The Goldman Sachs Group upgraded IDEAYA Biosciences to a “hold” rating and set a $25.00 price objective for the company in a research report on Thursday, July 10th. TD Cowen initiated coverage on IDEAYA Biosciences in a research note on Tuesday, July 22nd. They issued a “buy” rating on the stock. Royal Bank Of Canada upgraded shares of IDEAYA Biosciences from an “outperform” rating to a “moderate buy” rating and dropped their target price for the company from $57.00 to $30.00 in a research report on Wednesday, July 9th. Finally, Citizens Jmp initiated coverage on shares of IDEAYA Biosciences in a research report on Thursday. They set a “mkt outperform” rating and a $41.00 target price on the stock. Twelve investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $45.77.

IDEAYA Biosciences Price Performance

Shares of IDYA opened at $25.83 on Thursday. IDEAYA Biosciences has a 1 year low of $13.45 and a 1 year high of $39.30. The company has a market capitalization of $2.26 billion, a price-to-earnings ratio of -6.82 and a beta of 0.12. The business has a 50-day moving average of $23.55 and a 200-day moving average of $20.59.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its quarterly earnings results on Tuesday, August 5th. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.03). The firm had revenue of $6.00 million during the quarter, compared to analysts’ expectations of $3.48 million. During the same quarter last year, the firm earned ($0.68) earnings per share. The company’s quarterly revenue was up NaN% on a year-over-year basis.

Institutional Investors Weigh In On IDEAYA Biosciences

Several hedge funds and other institutional investors have recently modified their holdings of IDYA. Raymond James Financial Inc. bought a new stake in shares of IDEAYA Biosciences during the fourth quarter valued at approximately $431,000. AXA S.A. grew its holdings in IDEAYA Biosciences by 20.1% during the fourth quarter. AXA S.A. now owns 249,702 shares of the company’s stock worth $6,417,000 after buying an additional 41,722 shares in the last quarter. Ameriprise Financial Inc. grew its holdings in IDEAYA Biosciences by 3.6% during the fourth quarter. Ameriprise Financial Inc. now owns 288,002 shares of the company’s stock worth $7,401,000 after buying an additional 10,072 shares in the last quarter. BNP Paribas Financial Markets grew its holdings in IDEAYA Biosciences by 37.5% during the fourth quarter. BNP Paribas Financial Markets now owns 38,692 shares of the company’s stock worth $994,000 after buying an additional 10,543 shares in the last quarter. Finally, Bank of America Corp DE grew its holdings in IDEAYA Biosciences by 5.9% during the fourth quarter. Bank of America Corp DE now owns 747,934 shares of the company’s stock worth $19,222,000 after buying an additional 41,390 shares in the last quarter. Institutional investors own 98.29% of the company’s stock.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.